Wells Fargo raised the firm’s price target on uniQure (QURE) to $65 from $30 and keeps an Overweight rating on the shares. The firm notes impressive 3-year update for AMT-130, with cUHDRS maintaining the strong result from 2-year data, delivering at the top end of expectation, along with a positive surprise on the key TFC endpoint now showing benefit, exceeding expectation. Wells thinks the setup for uniQure is compelling into Q1 2026 BLA filing and FDA approval later in the year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets
- uniQure Announces Positive Results for Huntington’s Study
- uniQure Secures $175 Million Loan Amendment
- uniQure’s Promising Advancements in Huntington’s Disease Treatment and Strong Financial Position Justify Buy Rating
- uniQure announces $200M ordinary shares offering